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ABSTRACT: Antimicrobial peptides are widely recognized as an excellent
alternative to conventional antibiotics. MSI-78, a highly effective and broad
spectrum AMP, is one of the most promising AMPs for clinical application.
In this study, we have designed shorter derivatives of MSI-78 with the aim of
improving selectivity while maintaining antimicrobial activity. Shorter 17-mer
derivatives were created by truncating MSI-78 at the N- and/or C-termini,
while spanning MSI-78 sequence. Despite the truncations made, we found a
17-mer peptide, MSI-78(4−20) (KFLKKAKKFGKAFVKIL), which was
demonstrated to be as effective as MSI-78 against the Gram-positive
Staphylococcus strains tested and the Gram-negative Pseudomonas aeruginosa.
This shorter derivative is more selective toward bacterial cells as it was less
toxic to erythrocytes than MSI-78, representing an improved version of
the lead peptide. Biophysical studies support a mechanism of action for
MSI-78(4−20) based on the disruption of the bacterial membrane
permeability barrier, which in turn leads to loss of membrane integrity and ultimately to cell death. These features point to a
mechanism of action similar to the one described for the lead peptide MSI-78.
KEYWORDS: antimicrobial peptides, pexiganan, MSI-78, antibiotic resistance, cytotoxicity, membrane models
■ INTRODUCTION
Antibiotic resistance is becoming a huge concern, with
recent reports from the World Health Organization (WHO)
showing worrying situations worldwide.1 Methicillin resistant
Staphylococcus aureus (MRSA) is one of the bacterial strains
that cause most alarm, it was estimated that 25% of S. aureus
isolates in the USA are resistant while this percentage can be
even higher in other countries.2 Resistance is also a problem
in Gram-negative bacteria, such as in the case of multiresistant
Pseudomonas aeruginosa, with statistics revealing that in some
countries multiresistant Pseudomonas represent up to 45% of
the isolates.3
The increasing emergency to combat resistant bacterial
strains has prompted the development of new generations of
antimicrobial agents, with antimicrobial peptides (AMP) being
one of the most promising alternatives.4−7
AMP are ubiquitous in nature, usually 10−50 residues in length,
and have the ability to interact with bacterial cell membranes most
often leading to membrane disruption.8−10 As their mode of
action does not involve specific interactions, bacteria are less
prone to acquire resistance to AMP.11 However, some resistance
mechanisms that involve alterations of the cell wall have been
identified.11,12
Although AMP are promising antibiotic alternatives, their
low stability and high toxicity prevent efficient therapeutic ap-
plication.13 Therefore, improving AMP potency and selectivity
toward bacterial cells is needed. AMP selectivity is mainly
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determined by charge and hydrophobicity. While net charge
is crucial in the establishment of electrostatic interactions
between the positively charged peptide and the negatively
charged lipid headgroup of the bacterial lipid bilayer,
hydrophobicity is determinant in the insertion of the AMP
into the lipid bilayer.14
Another concern for bringing AMP into therapeutic
applications is the high cost of production associated with
peptide synthesis. Therefore, developing short AMP with
higher bacterial cell selectivity is the purpose of this study.13 In
fact, it has been reported that AMP length affects cytotoxicity,
for example a 15 residue shortened melitin and a shorter
derivative of HP(2−20) were 300 times less toxic to
erythrocytes than their parent peptides.15−17
MSI-78 is a well-studied AMP, commercially known as
pexiganan, developed for the treatment of infected diabetic
foot ulcers.18,19 This peptide has a broad spectrum of activity,
being effective against Gram-positive and Gram-negative
bacteria.18,20 MSI-78 belongs to the class of α-helical AMPs,
and it has been described to form dimers stabilized by
hydrophobic interactions.21 Moreover, it is known that the
MSI-78 mechanism of action involves disruption of bacterial
membranes via toroidal-type pore formation.20 Being one of the
best-studied and efficient AMPs, MSI-78 is an excellent lead
peptide to create shorter derivatives.
In this work, we aimed at creating a shorter MSI-78 de-
rivative while maintaining antimicrobial activity. We identified a
17-mer peptide, MSI-78(4−20), which was demonstrated to be
as effective as MSI-78 against all strains tested, despite the
truncations made.
With the help of model biomembrane systems we unraveled
the mechanism of action of MSI-78(4−20). Model membranes
composed of different phospholipids that mimic bacterial and
mammalian cell membrane were chosen as they are excellent
models to characterize the interactions between membrane
active compounds and bacterial or mammalian membranes. To
mimic the mammalian membrane 1,2-dimyristoyl-sn-glycero-
phosphocholine (DMPC) was chosen as it is widely used.22,23
To mimic the bacterial membrane, a mixture of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoglycerol (POPG) at 1:1 molar ratio
was chosen as it has been described as one of the most biologically
relevant model membranes for studying the S. aureus strain.24
■ EXPERIMENTAL SECTION
Reagents. Nα-Fmoc-protected amino acids, Rink amide AM
resin, and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) for solid phase peptide syn-
thesis (SPPS) were from NovaBiochem-EMD4Biosciences
(Darmstadt, Germany). N-Ethyl-N,N-diisopropylamine
(DIEA), 1-hydroxybenzotriazole (HOBt), trifluoroacetic acid
(TFA), triisopropylsilane (TIS), piperidine, and all solvents
for SPPS were from Sigma-Aldrich (St. Louis, MO, USA).
Octadecylsilane stationary phase 238TPB1520 for peptide
purification by medium-pressure reverse-phase liquid chroma-
tography (MP-RPLC) was from Vydac (Hesperia, CA, USA).
The lipids, 1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
(POPG) with a purity grade >98% were also purchased from
Sigma-Aldrich Co. Hepes buffer used in the biophysical experi-
ments with LUVs consisted of 10 mmol L−1 N-(2-hydroxyethyl)-
piperazine-N′-(2-ethanesulfonic acid), and the ionic strength was
adjusted to 0.1 M with sodium chloride and the pH to 7.4.
In the circular dichroism (CD) experiments, the buffer con-
sisted of 10 mmol L−1 sodium phosphate buffer, and the ionic
strength was adjusted to 0.1 M with sodium fluoride and the
pH to 7.4. Hepes and sodium phosphate buffer were supplied
by Sigma-Aldrich Co. (St. Louis, MO, USA). All the other
chemicals were purchased from Merck.
Peptide Design and Synthesis. Peptide sequences were
designed in order to obtain 17-mer peptides based on MSI-78
sequence, while spanning the entire sequence with one 1 AA
shifts with the aim of identifying shorter but still active
fragments of MSI-78 (Table 1). The 17-mer length was chosen
as it is an intermediate size between the 22-mer MSI-78 and the
12-mer short derivatives of MSI-78, that considerably lost its
spectrum of activity as previously described by us.25 Moreover,
it has been shown that truncating peptides while maintaining a
length above 15 AA may preserve antimicrobial activity.26
All peptides (Table 1) were prepared as C-terminal amides
by standard Fmoc/tBu SPPS on a Liberty1 microwave (MW)
peptide synthesizer (CEM Corporation, Mathews, NC,
USA).27 Briefly, Rink amide AM resin was preswelled for 15 min
in N,N-dimethylformamide (DMF) and then transferred
into the MW-reaction vessel. The initial Fmoc deprotection
step was carried out using 20% piperidine in DMF containing
0.1 M HOBt in two MW irradiation pulses: 30 s at 24 W plus
3 min at 28 W, in both cases temperature being kept under
75 °C. The Fmoc-protected C-terminal amino acid (Bachem,
Switzerland) was then coupled to the resin, using 5 molar equiv
of the Fmoc-protected amino acid in DMF (0.2 M), 5 equiv
of 0.5 M HBTU/HOBt in DMF, and 10 equiv of 2 M DIEA in
N-methylpyrrolidone (NMP); the coupling step was carried out
for 5 min at 35 W MW irradiation, with maximum temperature
kept below 75 °C. The remaining amino acids were sequentially
coupled in the C → N direction by means of similar
deprotection and coupling cycles. Following completion of
sequence assembly, the peptides were released from the resin
with concomitant removal of side-chain protecting groups, by a
3 h acidolysis at room temperature using a TFA-based cocktail
containing TIS and water as scavengers (TFA/TIS/H2O
95:2.5:2.5 v/v/v). Crude products were purified by MP-
RPLC to a purity of at least 95%, as confirmed by high-
performance liquid chromatography (HPLC) analysis on a
Hitachi-Merck LaChrom Elite system equipped with a
quaternary pump, a thermostated (Peltier effect) automated
sampler, and a diode-array detector (DAD). Pure peptides were
quantified by UV-absorption spectroscopy (Helios Gama,
Spectronic Unicam) and their molecular weights confirmed
to be as expected by electrospray ionization/ion trap mass
Table 1. Amino Acid Sequences of Synthetic Peptides
Derived from MSI-78a
peptides amino acid sequence
MSI-78 GIGKFLKKAKKFGKAFVKILKK 22 AA
MSI-78(1−17) GIGKFLKKAKKFGKAFV 17 AA
MSI-78(2−18) IGKFLKKAKKFGKAFVK
MSI-78(3−19) GKFLKKAKKFGKAFVKI
MSI-78(4−20) KFLKKAKKFGKAFVKIL
MSI-78(5−21) FLKKAKKFGKAFVKILK
MSI-78(6−22) LKKAKKFGKAFVKILKK
aThe 17-mer peptides were designed to span MSI-78 by 1-residue
shift.
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spectroscopy (ESI/IT MS; LCQ-DecaXP LC−MS system,
ThermoFinnigan).
Microorganisms and Growth Conditions. Microorgan-
isms tested in this study were the following: Staphylococcus
aureus (S. aureus) ATCC 33591 (methicillin resistant), S aureus
ATCC 25932, Staphylococcus epidermidis ATCC 35984, and
P. aeruginosa ATCC 27853. Bacteria were grown on trypticase
soy agar (TSA) plates and Mueller−Hinton broth (MHB).
Antimicrobial Testing. Antimicrobial activity was assessed
by minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC). The method used to
determine the MIC was the broth microdilution assay in
microtiter plates, described by Wiegand and co-workers.28 This
method follows the guidelines of the two recognized
organizations, CLSI and EUCAST. Bacteria were precultured
on TSB overnight at 37 °C and 150 rpm. After washing with
phosphate buffered saline (PBS), bacteria were adjusted to
approximately 2 × 105 CFU/mL in MHB, and 99 μL was
transferred to a 96 well plate. Polypropylene microtiter plates
were used to prevent binding of the peptides to the walls of the
wells. Peptide dilutions were prepared in acetic acid/bovine
serum albumin (BSA) solution, and peptide concentrations
tested ranged from 512 μg/mL to 0.015 μg/mL, adjusted
according to results obtained in preliminary experiments.
The peptides were tested in a final volume of 110 μL.
The minimum bactericidal concentration (MBC) was
determined by plating the content of the first three wells
where visible growth was not observed.
Hemolysis Assay on Human Red Blood Cells (RBC).
Human blood buffy coats were obtained from healthy volunteers
(Centro Hospitalar de Saõ Joaõ, EPE, Porto, Portugal) and
processed to obtain RBC by centrifugation over density gradient
with Histopaque-1077, Sigma-Aldrich Co. (St. Louis, MO, USA)
according to the manufacturer’s instructions. After removal of the
plasma upper layer, the lower layer containing RBC was washed
three times in PBS. The purified RBC were diluted to (6−7) ×
108 cells/mL in PBS, and 99 μL was distributed in a 96 well
polypropylene microtiter plate.
Peptide dilutions were prepared in acetic acid/BSA solution,
and the range of peptide concentrations tested went from
512 μg/mL to 1 μg/mL. After 1 h of incubation at 37 °C under
5% CO2, cells were centrifuged at 900 g for 10 min, and the
supernatant was transferred to a 96 well plate. The absorbance
values of the released hemoglobin were determined at 450 nm
using a microplate reader (SynersyMx, Biotek). Untreated
cells were used as negative control and cells treated with 0.2%
Triton X-100 as positive controls. The percentage hemolysis
was calculated as [(sample absorbance − negative control
absorbance)/(positive control absorbance − negative control
absorbance)] × 100.
Preparation of Cell Membrane Models: Large Uni-
lamellar Vesicles (LUVs). Lipid films were formed from
chloroform solution of DMPC and POPC:POPG 1:1 molar
ratio lipids, dried under a stream of nitrogen and left under
reduced pressure for a minimum of 45 min, to remove all traces
of the organic solvent. LUVs were prepared by the addition of
the buffer, followed by vortexing, yielding multilamellar vesicles
(MLVs). Lipid suspensions were equilibrated at 37.0 ± 0.1 °C
for 30 min and extruded 10 times through polycarbonate filters
with a diameter pore of 100 nm to form LUVs, as previously
described.23
ζ-Potential of LUVs. The ζ-potential of LUVs in the
absence and in the presence of AMP was assessed through the
determination of the electrophoretic mobility using a ZetaPALS
(Brookhaven Instruments Corporation). Typically 10 runs
were performed and the temperature was maintained at 37.0 ±
0.1 °C, the lipid concentration being kept constant at 200 μM,
and AMP concentration ranged from 0−40 μM.
Hydrodynamic Diameter. The hydrodynamic diameters
of LUVs in the absence and in the presence of AMP were
determined in a BI-MAS dynamic light scattering (DLS)
instrument (Brookhaven Instruments, USA). Typically 6 runs
(2 min each) were performed at the temperature of 37.0 ±
0.1 °C, the cumulate analysis being applied to scattering data to
give effective diameters and polydispersity.
Circular Dichroism (CD) Analysis. The secondary struc-
ture of the peptides MSI-78(4−20) and MSI-78 was investi-
gated using CD on a JASCO J-815 spectropolarimeter,
equipped with a temperature-controlled cuvette and controlled
by the Spectra manager software.
Peptide solutions were diluted in 10 mM sodium phosphate,
pH 7.4, 100 mM sodium fluoride to a concentration of 40 μM
with and without 5 mM DMPC or POPC:POPG 1:1 molar
ratio LUVs, corresponding to a peptide:lipid molar ratio of
1:125.
Before the measurement all peptide solutions were incubated
at 37 °C for 30 min. Far-UV CD spectra were recorded be-
tween 195 and 260 nm using a 1 mm path length cuvette. CD
spectra were acquired with a scanning speed of 100 nm/min
and an integration time of 1 s, and using a bandwidth of 1 nm.
The spectra were averaged over 16 scans and corrected by
subtraction of the buffer or buffer plus LUVs signal.
The results are expressed as the mean residue ellipticity
θMRW, defined as θMRW = θobs(0.1 MRW)/(lc), where θobs is the
observed ellipticity in millidegrees, MRW is the mean residue
weight, c is the concentration in mg/mL, and l is the light path
length in centimeters.
The mean helix content ( f H) was calculated according to
Luo and Baldwin, 1997.29 Briefly, f H is obtained from the θMRW
at 222 nm of each peptide (θ222) according to the equation fH =
(θ222 − θC)/(θH − θC), where the baseline ellipticities for
random coil (θC) and complete helix (θH) are given by θC =
2220 − 53T and θH = (−44000 + 250T)(1 − 3/N), where T is
the temperature in °C and N is the chain length in number of
residues.
■ RESULTS
Antimicrobial Activity. MIC of MSI-78 and its 17-mer
derivatives against the Gram-positive S. aureus and S.
epidermidis and the Gram-negative P. aeruginosa are described
in Table 2.
Regarding Gram-positive S. aureus strains, the 17-mer
peptide MSI-78(4−20) was the most effective with MIC values
of 32 μg/mL for the MRSA strain and 8−16 μg/mL for the
nonresistant S. aureus strain. Similar MIC values were obtained
with the lead peptide (MSI-78). MSI-78(1−17) maintained
also a high antimicrobial activity with MIC values of 64−
128 μg/mL for the MRSA strain and 32 μg/mL for the
nonresistant S. aureus strain. The MRSA strain is slightly less
susceptible to the peptides than the nonresistant strain. S.
epidermidis ATCC 35984 was more susceptible to the MSI-78
derivatives than S. aureus with all the 17-mer peptides being
effective with MIC values ranging from 2 to 32 μg/mL. Still,
MSI-78(4−20) also proved to be the most effective 17-mer
derivative against this strain. Results for the Gram-negative
P. aeruginosa demonstrate that this strain is much more
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susceptible to the 17-mer peptides and to MSI-78 than Gram-
positive Staphylococcus strains. All 17-mer peptides maintained
the antibacterial effect with MIC values below 8 μg/mL,
the MIC for MSI-78 being exceptionally low, 0.5−1 μg/mL.
MSI-78(4−20) was the most effective of all 17-mer derivatives
also against P. aeruginosa.
Overall, we found two 17-mer peptides, MSI-78(4−20) and
MSI-78(1−17), that maintained high spectrum of activity,
being effective against all strains tested, with MSI-78(4−20)
standing out, as it demonstrated to be equipotent to MSI-78.
MBC results were in general within the same range or 2-fold
higher than MIC results, indicating bactericidal effect of the
peptides for the concentrations tested.
MSI-78 antimicrobial activity was in general found to be in
line with previously published studies. Although MSI-78 MIC
values obtained for S. epidermidis and P. aeruginosa are slightly
lower than published data, some variation is reported in the
literature for these strains.18,20,30
Hemolytic Activity. Cytotoxicity studies were performed
with MSI-78 and MSI-78(4−20), as it demonstrated to be as
effective as the lead peptide.
MSI-78(4−20) was less cytotoxic to RBC than the lead
AMP, MSI-78 (Figure 1). MSI-78 showed some toxicity at high
concentrations (53% hemolysis at 512 μg/mL, 25% hemolysis
at 256 μg/mL, and 13% hemolysis at 128 μg/mL), which is in
agreement with previously published data.31 The 17-mer
peptide, MSI-78(4−20), showed very low toxicity to RBC
even at the higher concentrations tested (4% hemolysis at
512 μg/mL, 2% hemolysis at 256 μg/mL, and 1% hemolysis at
128 μg/mL).
AMP Interaction with Membrane Mimetic Systems.
ζ-Potential. The ζ-potential of DMPC and POPC:POPG
LUVs in the absence and in the presence of the AMPs MSI-
78(4−20) and MSI-78 is represented in Figure 2. The
determined ζ-potential of the zwitterionic DMPC LUVs was as
expected close to zero.32 In the presence of MSI-78(4−20) or
MSI-78, the ζ-potential remains nearly unchanged (Figure 2A).
The addition of increased concentrations of either peptide
to DMPC LUVs caused almost no alteration on the zeta poten-
tial values, suggesting a weak interaction or non-interaction
with the mammalian membrane model. The ζ-potential of
POPC:POPG LUVs was as expected negative, being signifi-
cantly altered by addition of either AMP and becoming
less negative as the concentration of MSI-78(4−20) and
MSI-78 increased (Figure 2B).33 An overall change from
approximately −28 mV to nearly neutral potential values was
achieved after the addition of both peptides (Figure 2B).
However, the variation of the ζ-potential values was even more
evident in the case of MSI-78 for lower concentrations (below
20 μM) of peptide (Figure 2B). These results suggest that the
positively charged peptides interact with the negatively charged
POPC:POPG LUVs, inducing changes in the membrane
surface charge by direct peptide binding and/or insertion in
the bacterial membrane model. The MSI-78 more pronounced
effect is probably due to the high positive charge displayed (+9)
in comparison to MSI-78(4−20) (+7), being consequently
more prone to establish electrostatic interactions with the
negatively charged bacterial membrane.
Hydrodynamic Diameter. The size of DMPC and
POPC:POPG LUVs in the absence and presence of different
concentrations of the AMPs MSI-78(4−20) and MSI-78 is
represented in Figure 3. In the absence of peptides, DMPC and
POPC:POPG LUVs presented a size of approximately 100 nm
(Figure 3A), as expected regarding their preparation. In the
presence of the peptides, DMPC LUVs exhibited a narrow
size distribution with a mean diameter of approximately
103−118 nm (Figure 3A), pointing to a weak influence or
noninfluence of both peptides in the mammalian cell
membrane model even at high peptide concentrations. On
the other hand, peptide interactions with POPC:POPG LUVs
induced a pronounced increase of the LUVs size, at peptide
concentrations higher than 10 μM (Figure 3B). Moreover, this
result is emphasized by the high polydispersity values obtained,
indicating the presence of a heterogeneous population
(polydispersity >0.1) (Figure 3B), and pointing to the existence
of aggregated structures. Therefore, bacterial membrane model
binding facilitates nucleation-dependent AMP aggregation. The
aggregation explains the larger mean hydrodynamic diameter
Figure 1. Hemolytic activity of MSI-78 and MSI-78(4−20) on human
RBC. Peptide concentrations tested covered a range from 512 μg/mL
to 1 μg/mL. Untreated bacterial cells were used as negative control,
and bacterial cells treated with 0.2% Triton X-100 were used as
positive control.
Table 2. Determination of MIC and MBC of MSI-78 and 17-mer Derivatives against Selected Microorganismsa
microorganisms
S. aureus (MRSA) S. aureus S. epidermidis P.aeruginosa
peptides MIC MBC MIC MBC MIC MBC MIC MBC
MSI-78 16−32 (6.5−13) 32 8−16 (3.2−6.5) 8−16 0.5−1 (0.2−0.4) 0.5−1 0.5−1 (0.2−0.4) 1−4
MSI-78(1−17) 64−128 256 32 32−64 4−8 8−16 0.5−2 2−4
MSI-78(2−18) >512 >512 16−32 32−64 4−8 >16
MSI-78(3−19) 512 >512 256 256−512 8−16 16−32 1−2 2−4
MSI-78(4−20) 32 (16) 64 8−16 (4−8) 16−32 2 (1) 2−4 0.25−1 (0.1−0.5) 1−4
MSI-78(5−21) 256 256−512 64−128 128−256 2−4 4 1−4 4−8
MSI-78(6−22) >512 >512 8−32 16−64 2−4 2−8
aMIC values are presented in μg/mL. Concentrations in μM are in parentheses.
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and polydispersity obtained in the case of POPC:POPG LUVs
for higher AMP concentrations.
AMP Structural Analysis (Secondary Structure). CD spectra
of MSI-78 and MSI-78(4−20) in aqueous buffer exhibited a
negative minimum at ≈198 nm suggesting random coil
conformations (Figure 4A). In the presence of DMPC LUVs,
spectra also exhibit characteristic profiles of unordered
peptides, pointing out to no toxicity toward mammalian cells
(Figure 4B). In the presence of POPC:POPG (1:1 molar ratio)
LUVs, two negative minima at ≈208 nm and ≈222 suggest the
presence of α-helical conformations (Figure 4C). For all
peptides, results indicate a transition from a random coil to an
ordered secondary structure upon interaction with the bacterial
membrane mimetic system POPC:POPG LUVs. In the
presence of this system, calculated mean helix contents show
slight differences between the peptides. The lead 22-mer
peptide MSI-78 has 62% helicity, whereas helicity values
around 40−45% have been reported by Mercke et al. for this
peptide when bound to POPC small unilamellar vesicles
(SUV).34,35 For MSI-78(4−20) the determined mean helix
content was 33%, which shows a difference of approximately
30% in the helix content between the two peptides.
Figure 4D represents the helical wheel projections of the
peptides where the relative position of the amino acids and its
polar/nonpolar character is displayed. Table 3 summarizes the
physicochemical properties and structural analysis of the
peptides. MSI-78(4−20) displays higher hydrophobicity and
higher hydrophobic moment than MSI-78. However, no
hydrophobic face is predicted for MSI-78(4−20) by Heliquest,
as it is not presenting a face of at least five uninterrupted
hydrophobic residues in the α-helix.36
■ DISCUSSION
In this study, we aimed at finding a short 17-mer fragment of
MSI-78, while maintaining MSI-78 antimicrobial activity. We
found two 17-mer fragments that maintained a high spectrum of
activity, MSI-78(1−17) and MSI-78(4−20). As MSI-78(4−20)
was as effective as MSI-78 against all strains tested, we chose
this peptide to study in more detail. Several physicochemical
parameters have been associated with a good AMP perform-
ance, among them: size, sequence, charge, secondary structure,
hydrophobicity, and amphipathicity. Although MSI-78(4−20)
is shorter and possesses a net charge lower than MSI-78,
hydrophobicity and amphipathicity parameters favor MSI-
78(4−20) antimicrobial activity. On the other hand, while MSI-
78(4−20) structures as an α-helix, the percentage of helicity is
about half when compared to MSI-78, however, this does not
seem to be determinant for antimicrobial activity. It has been
shown that AMP secondary structure and biological activity are
not always coupled.37,38 The absence of a glycine in the
N-terminus of MSI-78(4−20) might contribute to the smaller
α-helical content in comparison to MSI-78 as the glycine
Figure 3. Hydrodynamic diameters of 200 μM DMPC (A) and POPC:POPG 1:1 molar ratio mixture (B) after 30 min incubation and stabilization
with MSI-78 and MSI-78(4−20) at 37 °C. Bars represent diameters (nm), and dots represent polydispersity. Error bars represent the standard
deviation of at least three independent experiments.
Figure 2. Zeta potential measurements of 200 μM DMPC (A) and POPC:POPG molar ratio 1:1 mixture (B) after 30 min incubation and
stabilization with MSI-78(4−20) and MSI-78 at 37 °C. Circles MSI-78, squares MSI-78(4−20). Error bars represent the standard deviation of at
least three independent experiments.
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N-capping stabilizing effect is well-known.39 The biophysical
studies show that both peptides interact preferentially with the
bacterial cell membrane model, the membrane disruption being
concentration-dependent.40 The proposed interaction of both
peptides with the bacterial membrane initiates with peptide
binding to the membrane surface through electrostatic
interactions, which is especially pronounced in the case of
MSI-78. In the case of MSI-78(4−20), its higher hydro-
phobicity (higher H and μH) can favor a deeper insertion
within the bacterial lipid bilayer, which may explain its ability to
exert a bacterial effect despite its lower ability to form
α-helices.41 These results are in line with the published MSI-
78 mechanism of interaction with bacterial membrane models,
involving induction of substancial changes in lipid bilayers via
positive curvature strain and toroidal pore formation.42
We have also found that MSI-78(4−20) is less hemolytic
than MSI-78, which represents a major advantage of the 17-mer
AMP as compared to the lead MSI-78. In fact, as MSI-78(4−20)
displays a lower net charge than MSI-78 (+7 and +9 res-
pectively), this can be determinant for the initial interaction
between the peptide and the mammalian membrane. While
hydrophobicity parameter values would point to a higher
hemolytic activity of MSI-78(4−20), this did not occur. It has
been reported that increase of H and μH substantially enhance
hemolytic activity, however, MSI-78(4−20) does not possess a
well-defined hydrophobic face, as predicted by Heliquest. For
MSI-78, such a hydrophobic face is predicted, which may
maximize the hydrophobic interactions of the nonpolar face of
the amphipathic helix and the lipid, in the case of α-helix
formation upon interaction with RBC.36,43−45 In fact,
disruption of the hydrophobic face with a lysine substitution
in the nonpolar sector of a helical wheel projection has been
observed to improve peptide selectivity, while reduction of
helical content has been associated with decreased hemolytic
activity.46,47
Therefore, the more pronounced hemolytic effect of MSI-78
may be attributed to the marked nonspecific hydrophobic
interactions between the peptide and the mammalian cell
membranes.
The perturbation of the lipid bilayers by a peptide is indeed
governed by a balance between electrostatic and hydrophobic
interactions. Our results clearly indicate the importance of the
balance of these forces, suggesting this effect to be highly
responsible for the MSI-78(4−20) improved selectivity toward
bacterial cells and the ability to overcome the hemolytic toxic
effects of MSI-78. Still, differences between the peptides
regarding interactions with the mammalian membrane model
DMPC LUVs were not observed, however a membrane model
does not mimic a mammalian cell with its inherent complexity.
In fact to obtain the full picture of the peptides’ mechanism of
Figure 4. CD spectra of peptides MSI-78 (solid line) and MSI-78(4−20) (dotted line) acquired in aqueous buffer (A) and in the presence of DMPC
(B) and POPC/POPG (C) LUVs. Heliquest helical wheel projection diagrams of MSI-78 and MSI-78(4−20) (D); apolar residues are represented
in yellow and polar residues in blue.
Table 3. Physicochemical Properties and Structural Analysis of MSI-78 and MSI-78(4−20)a
peptides mol wt charge H μH aliphatic index predicted hydrophobic faceb helicity (% helix)
MSI-78 2476 +9 0.241 0.674 93.18 FFFAILGLV 62%
MSI-78(4−20) 1995 +7 0.322 0.704 97.65 none 33%
aThe values for net charge (z), hydrophobicity (H), and mean hydrophobic moment (μH) were assessed using the analysis module of Heliquest.36
Aliphatic index was obtained using The Collection of Anti-Microbial Peptides (CAMP). bHydrophobic face predicted by Heliquest; this algorithm
detects the existence of an uninterrupted hydrophobic face of at least 5 residues adjacent on a helical wheel.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.5b00113
Mol. Pharmaceutics 2015, 12, 2904−2911
2909
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
D
A
D
E 
D
O
 P
O
RT
O
 0
11
00
 o
n 
A
ug
us
t 2
8,
 2
01
5 
| ht
tp:
//p
ubs
.ac
s.o
rg 
 
Pu
bl
ic
at
io
n 
D
at
e 
(W
eb
): 
Ju
ly 
1, 
20
15
 | d
oi:
 10
.10
21/
acs
.m
olp
har
ma
ceu
t.5
b00
113
action, more detailed studies will need to be carried out,
including the use of more complex membrane models with
other compounds present in biological membranes (e.g.,
cholesterol, phosphatidylethanolamines, proteins), and also
intact cells.48 Nevertheless, the biophysical properties reported
in this study will be useful in designing membrane specific
antimicrobial peptides.
In this study, we found a very effective and broad-spectrum
AMP, MSI-78(4−20). This MSI-78 derivative is as effective as
the lead peptide, while having reduced hemolytic activity, thus
representing an improved version of MSI-78. We can envisage a
wide application for this AMP in the field of antimicrobial
research and possibly in the field of anticancer therapy, as a
number of other synthetic magainin analogues demonstrated
promising anticancer activity.49
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